Clinical Trials Logo

Clinical Trial Summary

An open-label, balanced, randomized, two-treatment, two-sequence, two-period, crossover, single dose oral relative bioavailability study of a novel PanCytoVir™ oral suspension (100 mg/mL) versus probenecid 500 mg tablets in normal healthy, adult, human subjects under fasting conditions.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06025344
Study type Interventional
Source TrippBio, Inc.
Contact David E. Martin, PharmD
Phone 3015381878
Email davidmartin@trippbio.com
Status Not yet recruiting
Phase Phase 1
Start date June 2024
Completion date October 2024

See also
  Status Clinical Trial Phase
Completed NCT02052349 - Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects Phase 1
Completed NCT01911741 - A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects Phase 1
Active, not recruiting NCT03154840 - Relative Bioavailability Among Different Eutropin Formulations Phase 1
Completed NCT04814472 - Healthy Volunteer Study Comparing Tablet and Oral Solution Formulations Phase 1
Completed NCT03934333 - A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS) Phase 1
Not yet recruiting NCT06025318 - An Evaluation of the Effect of Food on the PK of a Novel PanCytoVir™ Suspension (100mg/ml), in Healthy, Adult Volunteers Phase 1
Completed NCT04686669 - A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations Phase 1
Completed NCT03483259 - To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers Phase 1
Completed NCT05296382 - Bioavailability of Tebipenem (SPR994) Crushed Tablet Phase 1